215 related articles for article (PubMed ID: 28950787)
1. Estimation of once-daily amikacin dose in critically ill adults.
Šíma M; Hartinger J; Cikánková T; Slanař O
J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
[TBL] [Abstract][Full Text] [Related]
2. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
[TBL] [Abstract][Full Text] [Related]
3. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Lugo G; Castañeda-Hernández G
Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
[TBL] [Abstract][Full Text] [Related]
4. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
[TBL] [Abstract][Full Text] [Related]
6. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
D'Arcy DM; Casey E; Gowing CM; Donnelly MB; Corrigan OI
BMC Pharmacol Toxicol; 2012 Nov; 13():14. PubMed ID: 23136834
[TBL] [Abstract][Full Text] [Related]
7. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.
Petitcollin A; Dequin PF; Darrouzain F; Vecellio L; Boulain T; Garot D; Paintaud G; Ternant D; Ehrmann S
J Antimicrob Chemother; 2016 Dec; 71(12):3482-3486. PubMed ID: 27516474
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction.
Ghaffari S; Hadi AM; Najmeddin F; Shahrami B; Rouini MR; Najafi A; Mojtahedzadeh M
Eur J Hosp Pharm; 2022 Mar; 29(e1):e67-e71. PubMed ID: 34588225
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
13. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of amikacin in a Korean clinical population.
Jang SB; Lee YJ; Park MS; Song YG; Kim JH; Kim HK; Ahn BS; Park K
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):371-81. PubMed ID: 21612744
[TBL] [Abstract][Full Text] [Related]
19. Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults.
Mahmoudi L; Mohammadpour AH; Niknam R; Ahmadi A; Mojtahedzdeh M
Anaesth Intensive Care; 2014 Mar; 42(2):228-33. PubMed ID: 24580389
[TBL] [Abstract][Full Text] [Related]
20. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
Marsot A; Guilhaumou R; Riff C; Blin O
Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
